159 related articles for article (PubMed ID: 34436960)
1. SARS-CoV-2 among the Potential Viral Triggers for Vogt-Konayagi-Harada Disease: First Case Report and Literature Review.
Santamaria A; Chang J; Savarain C
Ocul Immunol Inflamm; 2022; 30(7-8):1869-1875. PubMed ID: 34436960
[TBL] [Abstract][Full Text] [Related]
2. Vogt-Koyanagi-Harada disease after SARS-CoV-2 infection: Case report and literature review.
Zou H; Zhang K; Chen X; Sha S
Immun Inflamm Dis; 2024 Apr; 12(4):e1250. PubMed ID: 38661242
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 Developed During Systemic Steroid Therapy for Vogt-Koyanagi-Harada Disease: A Case Report.
Niidome S; Usui Y; Tsubota K; Sugawara R; Goto H
Ocul Immunol Inflamm; 2023 Aug; 31(6):1305-1309. PubMed ID: 37084286
[TBL] [Abstract][Full Text] [Related]
4. A COVID-19 perspective of Vogt-Koyanagi-Harada disease.
Dutta Majumder P; Sadhu S; González-López JJ; Mochizuki M
Indian J Ophthalmol; 2023 Jun; 71(6):2587-2591. PubMed ID: 37322685
[TBL] [Abstract][Full Text] [Related]
5. Possible Association between Vogt-Koyanagi-Harada Disease and Coronavirus Disease Vaccine: A Report of Four Cases.
de Queiroz Tavares Ferreira F; Araújo DC; de Albuquerque LM; Bianchini PM; Holanda EC; Pugliesi A
Ocul Immunol Inflamm; 2023 Aug; 31(6):1134-1140. PubMed ID: 35914285
[TBL] [Abstract][Full Text] [Related]
6. Unusual Case of Vogt-Koyanagi-Harada Syndrome Presenting as Non-specific Headache.
A V P; Kumar J S A; K N N; Rao S; Shetty S
J Clin Diagn Res; 2014 Apr; 8(4):VD06-VD07. PubMed ID: 24959501
[TBL] [Abstract][Full Text] [Related]
7. Case report: Bilateral panuveitis resembling Vogt-Koyanagi-Harada disease after second dose of BNT162b2 mRNA COVID-19 vaccine.
Sato T; Nihei R; Sora D; Nishio Y; Takeuchi M
Front Immunol; 2022; 13():967972. PubMed ID: 36248859
[TBL] [Abstract][Full Text] [Related]
8. Vogt-Koyanagi-Harada Disease and COVID.
Manni P; Saturno MC; Accorinti M
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834885
[TBL] [Abstract][Full Text] [Related]
9. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
Brambati M; Giuffrè C; Marchese A; Bandello F; Modorati GM; Miserocchi E
Eur J Ophthalmol; 2022 Jan; 32(1):NP109-NP113. PubMed ID: 32998540
[TBL] [Abstract][Full Text] [Related]
10.
Brunet de Courssou JB; Tisseyre M; Hadjadj J; Chouchana L; Broca F; Terrier B; Duraffour P; Henriquez S
Ocul Immunol Inflamm; 2022 Jul; 30(5):1292-1295. PubMed ID: 35113742
[TBL] [Abstract][Full Text] [Related]
11. Vogt-Koyanagi-Harada Disease following mRNA-1273 (Moderna) COVID-19 Vaccination.
Joo CW; Kim YK; Park SP
Ocul Immunol Inflamm; 2022 Jul; 30(5):1250-1254. PubMed ID: 35404752
[TBL] [Abstract][Full Text] [Related]
12. Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan.
Herbort CP; Mochizuki M
Int Ophthalmol; 2007; 27(2-3):67-79. PubMed ID: 17468832
[TBL] [Abstract][Full Text] [Related]
13. Bilateral Panuveitis Mimicking Vogt-Koyanagi-Harada Disease following the First Dose of ChAdOx1 nCoV-19 Vaccine.
Kim SY; Kang MS; Kwon HJ
Ocul Immunol Inflamm; 2022 Jul; 30(5):1218-1221. PubMed ID: 35113750
[TBL] [Abstract][Full Text] [Related]
14. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome.
Wong RK; Lee JK; Huang JJ
Retin Cases Brief Rep; 2012; 6(4):423-6. PubMed ID: 25389947
[TBL] [Abstract][Full Text] [Related]
15. Acute-onset Vogt-Koyanagi-Harada like uveitis following Covid-19 inactivated virus vaccination.
Chen X; Wang B; Li X
Am J Ophthalmol Case Rep; 2022 Jun; 26():101404. PubMed ID: 35165663
[TBL] [Abstract][Full Text] [Related]
16. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report.
Kikuchi R; Kawagoe T; Hotta K
BMC Ophthalmol; 2020 Jun; 20(1):252. PubMed ID: 32580711
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination.
Papasavvas I; Herbort CP
J Ophthalmic Inflamm Infect; 2021 Jul; 11(1):21. PubMed ID: 34224024
[TBL] [Abstract][Full Text] [Related]
18. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
De Domingo B; López M; Lopez-Valladares M; Ortegon-Aguilar E; Sopeña-Perez-Argüelles B; Gonzalez F
Cells; 2022 Mar; 11(6):. PubMed ID: 35326462
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 Vaccine-Related Vogt-Koyanagi-Harada Disease Complicated by Central Serous Chorioretinopathy during Treatment Course: Case Report and Literature Review.
Han R; Xu G; Ding X
Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366301
[TBL] [Abstract][Full Text] [Related]
20. Early resolution of subretinal fluid without high-dose corticosteroids in a pregnant patient with Vogt-Koyanagi-Harada disease: a case report.
Sugita K; Mizumoto K; Kato N; Zako M
J Ophthalmic Inflamm Infect; 2015; 5():20. PubMed ID: 26140057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
